kiorapharma.com (KPRX) - Long-Term Debt to Capital Coefficient

Kiora Pharmaceuticals (KPRX) brings together a compact staff of experts in rare visual pathologies, where flexibility and personal commitment are highly valued. The company is currently undergoing the preclinical testing phase for small molecules, awaiting regulatory approval to strengthen its market position. The market trend for share prices with the 0.01 indicator reflects the dynamics of a business that attracts ophthalmologists with the opportunity for unique research backed by guaranteed financial support.

This indicator measures the proportion of long-term liabilities within the equity structure to assess financial leverage. In the case of Kiora Pharmaceuticals (KPRX), such funds are typically allocated toward costly ophthalmological tests and the maintenance of patent protection. By analyzing the ratio of loans exceeding one year to equity, one can evaluate the business development's dependence on borrowed resources. The trend of this metric reveals asset impairment risks during periods of rising interest rates. A low debt load confirms the high resilience of the company's capital.